Printed from: Cancer Advice
  http://www.canceradvice.com/

Print Page
Print

Blog
35
06/05/2014 12:19 PM Posted by: Dr. H. Alejandro Preti
Annual Meeting ASCO excerpts
Share Categoried under:  Cancer NewsClinical Trials
34
02/03/2014 05:50 PM Posted by: Dr. H. Alejandro Preti
The future of PD-1 and PD-L1 inhibitors in non-small cell lung cancer looks bright.
Share
32
06/23/2013 10:08 AM Posted by: Dr. H. Alejandro Preti
Dr. Pazdur's position and the FDA drug approval process.
Share Categoried under:  FDA Approval
31
04/21/2013 02:05 PM Posted by: Dr. H. Alejandro Preti
Immunoconjugates like Brentuximab Vedotin (Adcetris) and TDM-1 (Kadcyla)
Share
30
04/04/2013 08:38 AM Posted by: Dr. H. Alejandro Preti
Cancer Link
Share Categoried under:  Clinical Trials
24
09/26/2011 11:10 AM Posted by: Dr. H. Alejandro Preti
Share
14
03/24/2011 01:39 PM Posted by: Dr. H. Alejandro Preti
¿Por qué vienen los pacientes de Latino América a Houston a verlo? ¿Qué ventajas tiene un paciente que se atiende con el Dr. Preti?
Share Categoried under:  Novedades sobre el Cáncer
8
03/22/2010 06:25 PM Posted by: Dr. H. Alejandro Preti
Share
6
01/14/2010 09:02 AM Posted by: Dr. H. Alejandro Preti
Share
4
11/19/2009 09:50 AM Posted by: Dr. H. Alejandro Preti
Value of mammograms as screening tools debate.
Share Categoried under:  Cancer News
3
11/10/2009 06:46 PM Posted by: Dr. H. Alejandro Preti
As the war on cancer enters its fifth decade, 51 studies stood out as examples of progress that occurred in the past year, as determined by the American Society of Clinical Oncology (ASCO) and reported in "Clinical Cancer Advances 2009." Reflecting input from specialists throughout the field, the ASCO annual report highlights research developments for nine types of cancer, as well as cancer disparities, quality of life and quality of care, and cancer prevention and screening. "As this report demonstrates -- and as history shows -- investment in clinical cancer research pays off," ASCO president Douglas Blayney, MD, of the University of Michigan in Ann Arbor, said in a statement included in the report. "Since 1990, cancer mortality rates have declined by 15%. Today, two-thirds of patients survive at least five years after diagnosis, compared to just half of patients 40 years ago." "Thanks to basic research advances, we are entering an era of personalized cancer medicine, in which treatment is tailored to the unique genetics of the individual," Blayney added. The entire report appears online in the Journal of Clinical Oncology, but here is a summary of developments related to some of the most common cancers. In an attempt to provide context and a diversity of viewpoints, MedPage Today, in collaboration with ABC News, solicited comments from cancer specialists who were not involved in developing the ASCO publication. As appropriate, their views are included with the review of cancer research highlights.
Share
2
10/22/2009 02:32 PM Posted by: Dr. H. Alejandro Preti
Primary Objective of Clinical Trial: To determine the response rates of patients with relapsed and/or refractory non Hodgkin lymphoma treated with a combination of Vorinostat and Bortezomib.
Blog Search

Categories

arrow View All arrow

Archives

201406June1
June 2014 (1)
201402February1
February 2014 (1)
201308August1
August 2013 (1)
201306June1
June 2013 (1)
201304April2
April 2013 (2)
201302February1
February 2013 (1)
201110October4
October 2011 (4)
201109September1
September 2011 (1)
201108August2
August 2011 (2)
201104April3
April 2011 (3)
201103March2
March 2011 (2)
201102February1
February 2011 (1)
201011November1
November 2010 (1)
201006June1
June 2010 (1)
201003March1
March 2010 (1)
201001January1
January 2010 (1)
200912December1
December 2009 (1)
200911November2
November 2009 (2)
200910October1
October 2009 (1)

All Content Rights Reserved , Cancer Advice
Captavi QixSuite™ - Hosted Marketing Automation Software © 2009